Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ped.15576 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention.
Blood Adv
August 2024
Immune Deficiency Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Chronic graft-versus-host disease (cGVHD) remains a significant problem for patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although in vivo lymphodepletion for cGVHD prophylaxis has been explored in the myeloablative setting, its effects after reduced-intensity conditioning (RIC) are not well described. Patients (N = 83) with hematologic malignancies underwent targeted lymphodepletion chemotherapy followed by a RIC allo-HSCT using peripheral blood stem cells from unrelated donors.
View Article and Find Full Text PDFRisk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
Front Immunol
March 2024
Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands.
Article Synopsis
- Unmodified donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation (alloSCT) can enhance the beneficial Graft-versus-Leukemia (GvL) effects but also pose a risk for severe Graft-versus-Host Disease (GvHD).
- Key factors influencing GvHD risk after DLI include patient-derived antigen-presenting cells, lymphocyte count, and recent viral infections, particularly in patients with acute leukemia or myelodysplastic syndrome.
- Results indicate that certain conditions, like the timing of DLI and mixed bone marrow chimerism, significantly impact the likelihood of developing GvHD, with those receiving DLI three months post-transplant facing higher risks associated with
Alemtuzumab-based reduced-intensity conditioning for XIAP deficiency.
Pediatr Int
November 2023
Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis.
Ther Adv Hematol
June 2020
Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.
We have performed allogeneic hematopoietic cell transplantation (allo-HCT) using a reduced intensity conditioning regimen for curative management of advanced myelofibrosis (MF). However, allo-HCT is rarely considered for elderly or patients with severe comorbidities due to high transplantation-related mortality. In those patients, an alemtuzumab-based non-myeloablative (NMA) conditioning regimen followed by stem cell transplantation could be a possible treatment that has been tried in sickle cell anemia showing stable mixed chimerism and improvement of the disease.
View Article and Find Full Text PDFCD52-negative T cells predict acute graft-versus-host disease after an alemtuzumab-based conditioning regimen.
Br J Haematol
October 2020
Department of Hematology, Oncology and Pneumology, University Cancer Center Mainz (UCT), University Medical Center Mainz, Mainz, Germany.
Allogeneic haematopoietic stem cell transplantation (HSCT) after a reduced-intensity conditioning (RIC) regimen with fludarabine, melphalan and alemtuzmab is an effective therapy for haematological malignancies. Alemtuzumab, a monoclonal antibody against CD52, a glycosylphosphatidylinositol-anchor-bound surface protein on lymphocytes, depletes T cells to prevent graft-versus-host disease (GVHD). Despite this, acute and chronic GVHD (a/cGVHD) remain life-threatening complications after HSCT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!